Welcome to our dedicated page for Imax SEC filings (Ticker: IMAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
From record-breaking box-office weekends to multi-year theater signings in China, IMAX Corporation’s financial pulse beats inside its SEC disclosures. Each 10-K details giant-screen installs, backlog totals, and revenue splits with exhibitors, while every 10-Q revisits film remastering margins and technology licensing momentum. Yet these insights hide in hundreds of pages of technical language.
Stock Titan’s AI translates those dense documents the instant they appear on EDGAR. Want IMAX insider trading Form 4 transactions? Real-time alerts surface each executive trade. Need the most recent IMAX quarterly earnings report 10-Q filing? Our summaries highlight per-screen averages and joint-venture revenue in plain English. Coverage spans every critical form:
- 10-K annual report – network size, backlog, risk factors simplified
- 10-Q quarterly earnings with AI commentary and trend visuals
- 8-K material events – new studio partnerships and technology launches explained
- Proxy statement – IMAX proxy statement executive compensation decoded
- Form 4 – IMAX Form 4 insider transactions real-time
Professionals use these outputs to monitor screen-count expansion, evaluate royalty streams, and track incentive alignment through IMAX executive stock transactions Form 4. If you ask, “understanding IMAX SEC documents with AI” or search for “IMAX earnings report filing analysis,” this page delivers. Our AI keeps every IMAX annual report 10-K simplified and IMAX 8-K material events explained at your fingertips, saving hours and sharpening decisions.
Robert D. Lister, Chief Legal Officer and Senior Executive Vice President of IMAX Corporation, reported a sale of common stock. On 09/15/2025 Mr. Lister sold 20,000 shares at a reported price of $32.80 per share under a 10b5-1 trading plan dated June 11, 2025. After the sale his reported beneficial ownership of common shares is 161,421. The filing also discloses his remaining equity holdings across compensation vehicles: 50,143 outstanding options and 70,609 restricted share units following the transaction. The Form 4 was filed individually and signed by an attorney-in-fact on Mr. Lister's behalf.
IMAX Corp filed a Form 144 to notify a proposed sale of 20,000 Class A Common Shares through Merrill Lynch on the NYSE with an approximate sale date of 09/15/2025. The filing reports an aggregate market value of $656,029 against 53,782,520 shares outstanding, indicating the sale represents a small fraction of the company's outstanding stock.
The 20,000 shares were acquired through vesting of restricted stock units (RSUs) issued as compensation on dates between 02/21/2018 and 03/07/2021 (2,456; 1,869; 15,203; 472 respectively). No securities sales by the filer in the past three months are reported, and the filer certifies no undisclosed material adverse information.
Kenneth Ian Weissman, IMAX Corp executive (Deputy General Counsel, Corporate Secretary & Chief Compliance Officer), reported option exercise and subsequent share sales on 08/14/2025. He exercised 7,072 stock options with an exercise price of $22.49 (options issued in 2019, expiring 03/07/2026) converting them into 7,072 common shares. The filing shows two dispositions the same day: sale of 7,072 shares at $25.6707 and sale of 8,000 shares at $25.6272.
Ownership changed from an opening balance of 34,133 common shares to a post-transaction balance of 26,133 common shares. The filing notes Mr. Weissman retains 17,021 restricted share units outstanding and that the exercised options were vested in installments between 2020 and 2023.
Form 144 notice for IMAX (IMAX) reports a proposed sale of 15,072 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $386,560.79 based on 53,782,520 shares outstanding. The approximate sale date is 08/14/2025 on the NYSE. The lots to be sold were largely acquired through restricted stock vesting on 03/07/2023 (multiple grants totaling 8,867 shares) and earlier vesting on 03/07/2021 (233 shares), plus an option exercise scheduled 08/14/2025 for 7,072 shares paid in cash. The filer states no securities of the issuer were sold in the past three months and attests they are not aware of undisclosed material adverse information.
Schedule 13G/A filed for IMAX Corp reports that Orbis Investment Management Limited and Allan Gray Australia Pty Ltd beneficially own a combined 5,113,033 shares of IMAX common stock (CUSIP 45245E109), representing 9.5% of the class. Orbis individually holds 5,093,213 shares with sole voting and dispositive power; Allan Gray Australia holds 19,820 shares. The filing lists Orbis (Bermuda) and Allan Gray Australia (Australia) as the reporting persons.
The statement is filed under a Schedule 13G/A and includes certifications that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of IMAX. The filing is signed by Matt Gaarder as Attorney-in-Fact with signature date 08/14/2025. The event date requiring the filing is noted as 06/30/2025.
FAQ
What is the current stock price of Imax (IMAX)?
What is the market cap of Imax (IMAX)?
